Biota Pharmaceuticals’ (AVIR) “Buy” Rating Reiterated at HC Wainwright
Separately, FBR & Co reaffirmed an outperform rating on shares of Biota Pharmaceuticals in a research report on Tuesday, May 31st. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $5.50.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) opened at 1.68 on Tuesday. The company’s 50-day moving average price is $1.40 and its 200 day moving average price is $1.47. The company’s market cap is $64.92 million. Biota Pharmaceuticals has a 12-month low of $1.23 and a 12-month high of $2.31.
Biota Pharmaceuticals (NASDAQ:AVIR) last announced its earnings results on Wednesday, September 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%. Equities analysts predict that Biota Pharmaceuticals will post ($0.85) earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of AVIR. California Public Employees Retirement System acquired a new position in Biota Pharmaceuticals during the second quarter valued at $139,000. BlackRock Fund Advisors acquired a new position in Biota Pharmaceuticals during the second quarter valued at $143,000. Towerview LLC acquired a new position in Biota Pharmaceuticals during the second quarter valued at $224,000. Dimensional Fund Advisors LP acquired a new position in Biota Pharmaceuticals during the second quarter valued at $290,000. Finally, BVF Inc. IL acquired a new position in Biota Pharmaceuticals during the second quarter valued at $292,000. 34.53% of the stock is owned by hedge funds and other institutional investors.
Biota Pharmaceuticals Company Profile
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.